Bleeding risk of endoscopic ultrasound‐guided fine‐needle aspiration in patients undergoing antithrombotic therapy

• DOI: 10.1111/den.12687
• Publication Date: 2016-06-15T18:57:23Z
• Authors: Tadahisa Inoue; Fumihiro Okumura; Hitoshi Sano; Yuji Kobayashi; Norimitsu Ishii; Yuta Suzuki; Shigeki Fukusada; Kenta Kachi; Takanori Ozeki; Kaiki Anbe; Hiroyasu Iwasaki; Takashi Mizushima; Kiyoaki Ito; Masashi Yoneda
• Keywords: Discontinuation; Cilostazol

Bleeding events related to endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) are rare. However, for patients treated with antithrombotic agents, the bleeding risk of EUS-FNA is uncertain. Hence, aim this study was assess event rate associated in receiving treatment.A retrospective conducted 742 consecutive who underwent solid lesions between 2008 and 2015. We compared rates among were not administered those whose agent use discontinued, continued treatment aspirin or cilostazol, heparin as a replacement.There 131 (17.7 %) agents. Seven experienced events, overall 0.9 % (7/742). All intraoperative; there no postoperative episodes. Subgroup analysis by revealed 1.0 (6/611), 0 (0/62), 1.6 (1/61), (0/8) non-administration, discontinuation continuation replacement groups, respectively. Only one severe necessitated hemostatic (1/742; 0.1 %); occurred patient non-administration group, treatment.The present found low incidence EUS-FNA-related treatment. The even while continuing cilostazol.